This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's Trumenba Vaccine Approved by European Commission
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.
Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact
by Zacks Equity Research
Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.
Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?
by Zacks Equity Research
We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.
Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals
by Zacks Equity Research
After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.
Regeneron Presents Positive Phase II Data on HoFH Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
Theravance/Mylan Presents Phase III Data on COPD Candidate
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Merck Presents Phase II Data on Chronic Cough Candidate
by Zacks Equity Research
Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.
Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session
by Zacks Equity Research
Compugen Ltd. (CGEN) shares rose over 10% in the last trading session.
Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
by Arpita Dutt
Quite a few deals were announced this week including by companies like Biogen (BIIB).
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1
by Zacks Equity Research
TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.
Bear of the Day: AMAG Pharmaceuticals (AMAG)
by Brian Hamilton
Licensing expenses, increased SG&A, and limited market share expansion are weighing this stock down.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.
STERIS (STE) Grapples with Headwinds: Should You Dump?
by Zacks Equity Research
On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.
Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.
Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.
Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip
by Zacks Equity Research
On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.
Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.